NH2-QGGYTMHQDQEGDTDAGLK-COOH is a synthetic peptide chain consisting of a primary amine group attached to lysine and a carboxyl group attached to glutamine.
Thalidomide-NH-C10-COOH (compound 6b) is a synthetic E3 ligase ligand-linker conjugate. This compound combines the Thalidomide-based von Hippel-Lindau (VHL) ligand with a linker commonly employed in PROTAC technology. [1]
Pomalidomide-C2-amido-(C1-O-C5-O-C1)2-COOH is a chemically synthesized compound, designed as an E3 ligase ligand-linker conjugate, integrating the cereblon ligand derived from Pomalidomide and a linker employed in PROTAC technology. This compound serves to facilitate targeted protein degradation through the modulation of E3 ligase activity, enabling the selective elimination of specific proteins of interest.
Thalidomide-NH-PEG4-COOH is a conjugate comprising an E3 ligase ligand-linker, utilized in the synthesis of dCBP-1. dCBP-1 itself functions as a powerful and selective heterobifunctional degrader targeting p300 CBP.
Thalidomide-NH-CBP p300 ligand 2 (P-007) is a PROTAC-based compound designed to degrade CBP and p300, acting as a functional antagonist (WO2020173440).
Thalidomide-NH-PEG2-COOH is a conjugate, synthesized as an E3 ligase ligand-linker, that incorporates the cereblon ligand derived from Thalidomide along with a linker commonly employed in PROTAC technology.
Thalidomide-NH-PEG3-COOH is a conjugate of the E3 ligase ligand-linker synthesized compound, which integrates a cereblon ligand based on Thalidomide and a linker employed in PROTAC technology.